Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 11%
Buy 22%
Hold 61%
Sell 6%
Strong Sell 0%

Bulls say

Amgen's financial outlook is bolstered by a significant 40% increase in sales in the third quarter of 2025 compared to the same period in the previous year, with 16 products experiencing double-digit growth, including notable contributions from Repatha and Tezspire. The company's recent guidance increase for FY25 revenue to a range of $35.8 billion to $36.6 billion underscores its robust performance across established franchises and the anticipated strong ramp-up of Uplizna due to label expansions. Furthermore, projections indicate worldwide Uplizna sales could surge to $1.4 billion by 2027, reflecting the positive momentum in Amgen's portfolio and its strategic growth initiatives.

Bears say

Amgen is projected to experience minimal total revenue growth of approximately 1% in 2026 compared to 2025, primarily due to anticipated significant sales declines of around 28% for Prolia and 39% for Xgeva. Management has indicated that research and development spending growth will be muted, which raises concerns regarding the company's ability to invest adequately in its pipeline to sustain future growth. Although emerging products like MariTide and olpasiran exhibit clinical potential, there is limited visibility on their ability to compensate for the anticipated base business erosion resulting from the loss of exclusivity for key franchises.

Amgen (AMGN) has been analyzed by 18 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 22% recommend Buy, 61% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 18 analysts, Amgen (AMGN) has a Hold consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $350.39, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $350.39, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.